A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels

Kowa Research Europe0 sites350 target enrollmentJuly 26, 2013

Conditionsdyslipidemia (eg hyperlipidaemia, hypertriglyceridaemia)MedDRA version: 18.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861 Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: dyslipidemia (eg hyperlipidaemia, hypertriglyceridaemia)
Sponsor: Kowa Research Europe
Enrollment: 350
Status: Active, not recruiting
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 26, 2013

End Date

TBD

Last Updated

10 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Kowa Research Europe

Eligibility Criteria

Inclusion Criteria

•Patients who meet the following criteria at screening will be eligible to participate in the study:
•1\. Able to understand and comply with study procedures and give written informed consent
•2\. Aged\>\=18 years
•3\. Have no clinically significant abnormal findings on medical history, physical examination, vital signs, 12\-lead electrocardiogram (ECG) and clinical laboratory profiles of both blood and urine that would impair participation or safety in the trial or clinically relevant abnormal findings that in the opinion of the investigator could interfere with the objectives of the study or the safety of the patient
•4\. After treatment with stable statin therapy for at least 12 weeks prior to screening, have a screening LDL\-C of no more than 10 mg/dL (0\.259 mmol/L) above the NCEP ATP III target (see Note 2 below):
•? \- LDL\-C\<70 mg/dL (1\.81 mmol/L) or \<100 mg/dL (2\.59 mmol/L) for patients with coronary heart disease (CHD) or CHD equivalent
•? \- LDL\-C\<130 mg/dL (3\.36 mmol/L) for patients with multiple risk factors
•? \- LDL\-C\<160 mg/dL (4\.14 mmol/L) for patients with 0\-1 risk factor
•Note 1: Any statin approved by the regulatory authority in the respective country is allowed, with the exception of pravastatin, lovastatin, and fluvastatin
•Note 2: If LDL\-C is greater than 10 mg/dL (0\.259 mmol/L) above target, patients are only eligible for the study if they are on the maximum allowable statin dose as per approved SPC in the respective country or on the maximum dose tolerated by the respective patient.

Exclusion Criteria

•Patients will be excluded from participation in the study if any of the following criteria apply:
•1\. Patients who require other lipid lowering treatments in addition to study drug (K\-877\) and statin
•2\. Patients with body mass index \=40 kg/m2
•3\. Patients with homozygous familial hypercholesterolaemia (heterozygous is permitted) or familial hypoalphalipoproteinaemia
•4\. Patients with type 1 diabetes mellitus
•5\. Patients with poorly controlled type 2 diabetes mellitus (haemoglobin A1c \>10%)
•6\. Patients who are receiving insulin or insulin analogue treatment except for stable basal insulin therapy with a single insulin
•7\. Patients with moderate or severe renal impairment (ie, estimated glomerular filtration rate \<50 mL/min/1\.73m2\) at screening
•8\. Patients with serious liver dysfunction; liver function test values \>3 × upper limit of normal (ULN) of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at screening
•9\. Patients with a creatine kinase level \>3 × ULN at screening